{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:14:21Z","timestamp":1768281261170,"version":"3.49.0"},"reference-count":39,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1080\/13696998.2021.1927746","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T18:48:15Z","timestamp":1620586095000},"page":"770-780","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7257-8675","authenticated-orcid":false,"given":"Carlos","family":"Acosta","sequence":"first","affiliation":[{"name":"Value & Market Access, Biogen International GmbH, Baar, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Gianinazzi","sequence":"additional","affiliation":[{"name":"Value & Market Access, Biogen International GmbH, Baar, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaut","family":"Dort","sequence":"additional","affiliation":[{"name":"Value & Market Access, Biogen International GmbH, Baar, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews, Ltd., York, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Ryder","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews, Ltd., York, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lundqvist","sequence":"additional","affiliation":[{"name":"Market Access, Biogen Sweden AB, Upplands V\u00e4sby, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Ekelund","sequence":"additional","affiliation":[{"name":"Market Access, Biogen Sweden AB, Upplands V\u00e4sby, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lycke","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.17925\/ENR.2011.06.02.110"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hch105"},{"key":"CIT0003","unstructured":"Rajagopalan K, Jones E, Pike J, et\u00a0al., editors. Emergence of walking and mobility problems among patients with multiple sclerosis and its impact on quality of life: a cross-sectional assessment in 5 EU countries. Paper presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2010 October 13\u201316; Gothenburg, Sweden."},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.1895"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-013-0028-x"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.2165\/11591150-000000000-00000"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-94"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-286"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517694432"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1159\/000331043"},{"key":"CIT0011","volume-title":"Global economic impact of multiple sclerosis","author":"Trisolini M","year":"2010"},{"key":"CIT0012","unstructured":"Biogen. Fampyra \u2013 summary of product characteristics [Internet]. European Medicines Agency; 2018 [cited 2020 Jul 22]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fampyra-epar-product-information_en.pdf"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-011-0214-y"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2014.983904"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22240"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60442-6"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515581436"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0586-5"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0683-9"},{"key":"CIT0020","unstructured":"Tandv\u00e5rds-L\u00e4kemedelf\u00f6rm\u00e5nsverket - TLV. Fampyra is included in the high-cost protection [Internet]. Stockholm (Sweden): Tandv\u00e5rds-l\u00e4kemedelsf\u00f6rm\u00e5nsverket; 2018 [cited 2020 Apr 9]. Available from: https:\/\/www.tlv.se\/beslut\/beslut-lakemedel\/generell-subvention\/arkiv\/2018-10-31-fampyra-ingar-i-hogkostnadsskyddet.html"},{"key":"#cr-split#-CIT0021.1","unstructured":"Tandv\u00e5rds-L\u00e4kemedelf\u00f6rm\u00e5nsverket - TLV. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2) [Internet]. Stockholm (Sweden): Tandv\u00e5rds-l\u00e4kemedelsf\u00f6rm\u00e5nsverket"},{"key":"#cr-split#-CIT0021.2","unstructured":"2003 [cited 2019 Jun 13]. Available from: https:\/\/www.tlv.se\/download\/18.2e53241415e842ce95514e9\/1510316396792\/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514563591"},{"key":"CIT0023","unstructured":"Schapiro RB, Brown F, Wiliamson T, et\u00a0al. Open-label extension patient retention rates with dalfampridine extended release tablets in multiple sclerosis. Paper presented at ECTRIMS 28th Congress (European Committee for Treatment and Research in Multiple Sclerosis); 2012 October 10\u201313; Lyon, France."},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300616"},{"key":"CIT0025","unstructured":"Statistics Sweden (SCB). Popular statistics [Internet]. 2017 [cited 2018 November 04] Available from: http:\/\/www.scb.se\/en\/"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1177\/2055217315596993"},{"key":"CIT0027","unstructured":"Krishnan AGA, Potts J, Cohen J. Health-related quality of life is reduced in multiple sclerosis patients whose walking speed declines over time. Paper presented at 64th AAN Annual Meeting (American Academy of Neurology); 2012 April 21\u201328; New Orleans, LA"},{"key":"CIT0028","doi-asserted-by":"crossref","unstructured":"Hobart J, Hupperts R, Linnebank M, et\u00a0al. Health-related quality of life improved in people with multiple sclerosis who had clinically meaningful changes in walking ability with PR-Fampridine: post hoc analysis of ENHANCE. Poster presented at the World Congress of Neurology; 2017 September 16\u201321; Kyoto, Japan.","DOI":"10.1016\/j.jns.2017.08.3486"},{"key":"CIT0029","doi-asserted-by":"crossref","unstructured":"Liu YMM, Lee A, Zhong J, et\u00a0al. Quality of life among patients with multiple sclerosis treated with prolonged-release fampridine 10\u2009mg tablets twice daily for walking impairment: post hoc analysis of the mobile study. Poster presented at the 17th Annual European Congress; 2014 November 8\u201312; Amsterdam, the Netherlands.","DOI":"10.1016\/j.jval.2014.08.918"},{"issue":"2","key":"CIT0030","first-page":"315","volume":"24","author":"Hupperts R","year":"2018","journal-title":"Mult Scler"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"CIT0032","unstructured":"Regionv\u00e5rdsn\u00e4mnden S. Regionala priser och ers\u00e4ttningar f\u00f6r S\u00f6dra sjukv\u00e5rdsregionen 2018 [Internet]. Lund (Sweden): S\u00f6dra regionv\u00e5rdsn\u00e4mndens kansli; 2017 [cited 2018 April 10]. Available from: http:\/\/sodrasjukvardsregionen.se\/avtal-priser\/regionala-priser-och-ersattningar\/"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-006-0379-5"},{"key":"CIT0034","unstructured":"XE. Xe currency converter [Internet]. 2021 [cited 2021 April 8]. Available from: https:\/\/www.xe.com\/currencyconverter\/"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0150-1"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1206328"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114287"},{"key":"CIT0038","volume-title":"Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial","year":"2016"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2021.1927746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T12:42:32Z","timestamp":1641386552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2021.1927746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"alternative-id":["10.1080\/13696998.2021.1927746"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2021.1927746","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}